35
Participants
Start Date
January 31, 2009
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
sulopenem and PF-03709270
Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
Sulopenem and PF-03709270
Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
Ceftriaxone and amoxicillin/clavulanate
IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
Infection Management Services, Building 17, Level 1, Brisbane
Summa Health System, Akron
Summa Health System, Akron
Summa Health System, Akron
Infectious Disease Minneapolis Limited, Minneapolis
Trinity Medical Center, Rock Island
Medical Arts Associates, Ltd, Moline
Utah Valley Pulmonary Clinic, Provo
Utah Valley Regional Medical Center, Provo
eStudySite, Inc., Chula Vista
Sharp Chula Vista Medical Center, Chula Vista
eStudySite, Inc., Oceanside
Tri-City Medical Center, Oceanside
Hamilton Health Sciences - General Site, Hamilton
Hamilton Health Sciences- McMaster Site, Hamilton
Hamilton Health Sciences - Henderson Site, Hamilton
Oddzial Chorob Wewnetrznych i Gastroenterologii, Bialystok
Oddzial Chorob Pluc, Brzesko
Kliniczny Oddzial Gruzlicy i Chorob Pluc, Krakow
Oddzial Kliniczny Pulmonologii i Alergologii, Lodz
Oddzial Pulmonologiczny III, Poznan
Oddzial Pulmonologiczny, Proszowice
II Oddzial Chorob Wewnetrznych, Warsaw
Asan Medical Center, Division of Infectious Diseases, Seoul
Lead Sponsor
Pfizer
INDUSTRY